Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients

ClinicoEconomics and Outcomes Research

Volumn 6, Issue , 2014, Pages 463-472

  Esposti, Luca Degli ^a   Saragoni, Stefania ^a   Buda, Stefano ^a   Esposti, Ezio Degli ^a  

^a Economics and Outcomes Research   (Italy)

Author keywords

Adherence; Clinical practice; Diabetes; Health care costs; Sitagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIASTHMATIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; RESPIRATORY TRACT AGENT; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DEMOGRAPHY; DIABETES CONTROL; DIABETIC PATIENT; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 84908250572     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S63666     Document Type: Article

References (38)

1. International Diabetes Federation [webpage on the Internet]. Diabetes atlas, 6th edition. Brussels, Belgium: International Diabetes Federation; 2009. Available from: http://www.diabetesatlas.org/content/diabetes. Accessed March 29, 2013.
2. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100(10):1134-1146.
3. Sobel BE, Schneider DJ. Cardiovascular complications in diabetes mellitus. Curr Opin Pharmacol. 2005;5(2):143-148.
4. National Diabetes Information Clearinghouse [webpage on the Internet]. National diabetes statistics, 2011. Available from:http://diabetes.niddk.nih.gov/statistics/index.aspx. Accessed March 29, 2013.
5. Lauro R, Nicolucci A. Public Health and Health Policy: An Informed Health Policy on Chronic Diseases. Scientific Editor: Consorzio Mario Negri Sud; 2011.
6. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52(1):17-30.
7. American Diabetes Association. Standard of medical care in diabetes-2012. Diabetes Care. 2012;35(Suppl 1):S11-S13.
8. Freeman JS. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs. J Am Osteopath Assoc. 2010;110(9):528-537.
9. Degli Esposti L, Saragoni S, Buda S, Sturani A, Degli Esposti E. Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases. Clinicoecon Outcomes Res. 2013;5:193-201.
10. Di Bari M, Balzi D, Roberts AT, et al. Prognostic stratification of older persons based on simple administrative data: development and validation of the “Silver Code,” to be used in emergency department triage. J Gerontol A Biol Sci Med Sci. 2010;65(2):159-164.
11. Ministero del lavoro, della Salute e delle Politiche Sociali. Rapporto annuale sulle attività di ricovero ospedaliero [Annual report on the activities of hospitalization]. 2009. Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1491_allegato.pdf. Accessed December 22, 2013. Italian.
12. Centers for Disease Control and Prevention [homepage on the Internet] International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM); [updated 2010 Sep 21; reviewed 2010 Sep 21; cited 2010 Nov 23]. Available from: http://www.cdc.gov/nchs/icd/icd9cm.htm. Accessed May, 13, 2013.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62-S69.
15. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074-1090; discussion 1073.
16. Cohen HW, Shmukler C, Ullman R, Rivera CM, Walker EA. Measurements of medication adherence in diabetic patients with poorly controlled HbA(1c). Diabet Med. 2010;27(2):210-216.
17. L’Informatore farmaceutico italiano [The Italian pharmaceutical informer]. Italy: Elsevier; 2012. Available from: http://www.informatorefarmaceutico.it/. Accessed April 11, 2013. Italian.
18. Gary TL, Crum RM, Cooper-Patrick L, Ford D, Brancati FL. Depressive symptoms and metabolic control in African-Americans with type 2 diabetes. Diabetes Care. 2000;23(1):23-29.
19. Skaer TL, Sclar DA, Markowski DJ, Won JK. Effect of value-added utilities on prescription refill compliance and Medicaid health care expenditures-a study of patients with non-insulin-dependent diabetes mellitus. J Clin Pharm Ther. 1993;18(4):295-299.
20. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004;9(4):197-204.
21. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
22. McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, Dahl M. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011;5(1):e35-e48.
23. Esposito K, Ceriello A, Giugliano D. Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes? Endocrine. 2013;44(2):343-345.
24. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25(3):512-516.
25. Solberg LI, Engebretson KI, Sperl-Hillen JM, Hroscikoski MC, O’Connor PJ. Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depression. Am J Med Qual. 2006;21(4):238-245.
26. Brown JB, Nichols GA, Glauber HS. Case-control study of 10 years of comprehensive diabetes care. West J Med. 2000;172(2):85-90.
27. McIntosh B, Cameron C, Singh SR, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011;5(1):e35-e48.
28. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303(14): 1410-1418.
29. Sicras Mainar A, Roldán Suárez C, Font Ramos B, Navarro Artieda R, Ibáñez Nolla J. Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients. Rev Clin Esp. 2013;213(8):377-384.
30. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient’s perspective. Ther Clin Risk Manag. 2008;4(1):269-286.
31. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65(3):314-322.
32. Zhang Y, McCoy RG, Mason JE, Smith SA, Shah ND, Denton BT. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care. 2014 May;37(5):1338-1345.
33. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14(36):1-248.
34. Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab. 2008;10 Suppl 1:43-55.
35. Granström O, Bergenheim K, McEwan P, Sennfält K, Henriksson M. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. Prim Care Diabetes. 2012;6(2):127-136.
36. Sinha A, Rajan M, Hoerger T, Pogach L. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes Care. 2010;33(4):695-700.
37. Klarenbach S, Cameron C, Singh S, Ur E. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ. 2011;183(16): E1213-E1220.
38. Reid T. Choosing GLP-1 receptor agonists or DPP-4 inhibitors: weighing the clinical trial evidence. Clinical Diabetes. 2012;30(1):3-12.